


Nayzilam[®] **IV**
(midazolam) nasal spray

**NOW
AVAILABLE**

**NAYZILAM IS THE FIRST AND ONLY
MIDAZOLAM NASAL SPRAY APPROVED
TO TREAT SEIZURE CLUSTERS.**

NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.

For your patients who need a rescue medication, NAYZILAM was clinically proven to stop seizure clusters.

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. The most common adverse reactions ($\geq 5\%$ in any NAYZILAM treatment group) were somnolence, headache, nasal discomfort, throat irritation, and rhinorrhea.

NAYZILAM is a nasal spray that treats seizure clusters in the outpatient setting



- Can be administered by a non-healthcare professional
- No priming or assembly necessary



- May be administered to a patient during or after a seizure within a cluster
- Requires no active inhalation



- Can be used wherever a seizure cluster occurs:
at home, school, or work

Important Safety Information


RISKS FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines, including NAYZILAM, and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Please see additional Important Safety Information on the back page and the full Prescribing Information provided by your UCB representative.

GET YOUR PATIENTS STARTED ON NAYZILAM

Please inform your patients to allow 24-48 hours for NAYZILAM® (midazolam) nasal spray, CIV to be delivered to their local pharmacy after the prescription has been received.



UCB IS COMMITTED TO HELPING PATIENTS ACCESS NAYZILAM

Because this is a new treatment, proactively submitting a prior authorization (PA) can help your patients access their therapy.

PA assistance is available through CoverMyMeds, a service that seamlessly connects your office with pharmacies and health plans involved in the PA process.

covermymeds®

Online service for the PA process

- Physician offices can initiate PA requests using the online portal or at the point of prescribing through one of the EHR vendors integrated with the CoverMyMeds technology.
- Health plans provide determinations, often in real-time, that are sent to both your office and the local pharmacy.



VISIT
COVERMYMEDS.COM



CALL
1-866-452-5017

If you need assistance submitting a PA, live support is available by phone.

SAVINGS OPTIONS FOR PATIENTS

Anticipated patient cost for 1 box (2 doses) of NAYZILAM

Commercial*	Approximately \$40 per box† Eligible patients could pay as little as \$20 with the NAYZILAM Patient Savings Card
Medicare*	Less than or equal to \$8.50 if Low Income Subsidy (LIS) patient Approximately \$150 during standard benefit phase for Medicare
Medicaid*	Less than \$10

* Anticipated cost after insurance provides coverage for NAYZILAM through PA approval
† May not apply to all prescriptions filled at certain pharmacies, including CVS



This savings card is not valid for use by patients who are covered by any federally funded or state-funded healthcare program (including, but not limited to, Medicare [Part D and Medigap] and those who are Medicare-eligible and enrolled in an employer-sponsored health plan for retirees, Medicaid, any state pharmaceutical assistance program, TRICARE, VA, or DoD), or for cash-paying patients. A valid NAYZILAM prescription consistent with the approved FDA labeling is required. Other Eligibility Criteria and Terms apply. Full Eligibility Criteria and Terms are available at www.NAYZILAM.com or upon request by calling [ucbCARES®](tel:1-844-599-CARE) at 1-844-599-CARE (2273).

Reference: NAYZILAM Prescribing Information. Smyrna, GA: UCB, Inc.

Nayzilam®
(midazolam) nasal spray

NAYZILAM DOSING AND STORAGE



Packaging and Storage

- Each box contains two single-use nasal spray devices
- Store at room temperature

Dosing

- **FIRST DOSE:** One 5 mg spray in one nostril
- **SECOND DOSE (if needed):** An additional 5 mg dose may be administered after 10 minutes in the other nostril

It is recommended that NAYZILAM® (midazolam) nasal spray, CIV be used to treat no more than one episode every three days and no more than five episodes per month



Important Safety Information (continued)

CONTRAINDICATIONS

NAYZILAM is contraindicated in patients with acute narrow-angle glaucoma.

CNS Depression from Concomitant Use with Other CNS Depressants, or Moderate or Strong CYP3A4 Inhibitors

NAYZILAM may cause an increased CNS-depressant effect when used with alcohol or other CNS depressants. Concomitant use of NAYZILAM with moderate or strong CYP3A4 enzyme inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including NAYZILAM, increase the risk of suicidal thoughts or behavior.

Impaired Cognitive Function

Midazolam, including NAYZILAM, is associated with a high incidence of partial or complete impairment of recall for several hours.

Please see the complete Important Safety Information at www.NAYZILAM.com and the full Prescribing Information provided by your UCB representative.

For patient resources, including the NAYZILAM Patient Savings Card and Patient Training Kit, please visit www.NAYZILAM.com

ucbCARES
Caring Answers

For more information about NAYZILAM or to request a specific medical follow-up, please contact ucbCARES®:



CALL

1-844-599-CARE (2273)



VISIT

www.askucbcares.com

 Inspired by patients.
Driven by science.

NAYZILAM® and ucbCARES® are registered trademarks of the UCB Group of Companies. All other trademarks are the property of their respective owners.
©2020 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-P-NZ-SC-2000014


Nayzilam® CIV
(midazolam) nasal spray